Millendo Therapeutics, Inc.
MLND · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 6/30/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | 0.00 | 0.00 | 0.00 |
| FCF Yield | 199.35% | 0.00% | 65.44% | -6.25% |
| EV / EBITDA | 0.20 | 0.44 | -0.81 | 9.46 |
| Quality | ||||
| ROIC | -43.19% | -45.12% | 74.72% | -9.88% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | -4.69 | -1.02 | – | -1.25 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 0.00% | -100.00% | 0.00% | 99.29% |
| Safety | ||||
| Net Debt / EBITDA | 0.71 | 0.77 | 0.83 | 9.67 |
| Interest Coverage | -173.17 | -67.93 | 16.30 | -24.58 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |